Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Capital Expenditures (2020 - 2025)

Treace Medical Concepts' Capital Expenditures history spans 6 years, with the latest figure at $2.4 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 21.99% year-over-year to $2.4 million; the TTM value through Dec 2025 reached $13.5 million, up 16.6%, while the annual FY2025 figure was $13.5 million, 16.6% up from the prior year.
  • Capital Expenditures reached $2.4 million in Q4 2025 per TMCI's latest filing, down from $2.8 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $5.9 million in Q3 2022 to a low of $196000.0 in Q1 2021.
  • Average Capital Expenditures over 5 years is $2.7 million, with a median of $2.6 million recorded in 2025.
  • The largest YoY upside for Capital Expenditures was 1518.97% in 2021 against a maximum downside of 70.92% in 2021.
  • A 5-year view of Capital Expenditures shows it stood at $900000.0 in 2021, then surged by 159.11% to $2.3 million in 2022, then dropped by 3.6% to $2.2 million in 2023, then skyrocketed by 36.74% to $3.1 million in 2024, then decreased by 21.99% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for TMCI's Capital Expenditures are $2.4 million (Q4 2025), $2.8 million (Q3 2025), and $4.8 million (Q2 2025).